Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Anti-Complement Therapy Decreases Endogenous Thrombin Potential in Patients with Cold Agglutinin Disease

Garrett Diltz, Andrew Tiu, Catherine M. Broome

Blood (2024) 144 (Supplement 1): 5231.

https://doi.org/10.1182/blood-2024-208495

Published: 2024

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Catherine M. Broome, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Jiangming Wu, Shruti Srivastava, Marek Wardęcki, Reena Patel, Ronnie Yoo, Alexander Röth

Blood (2024) 144 (Supplement 1): 7667.

https://doi.org/10.1182/blood-2024-206942

Published: 2024

Journal Articles

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Shirley D'Sa, Carlos M de Castro, Satheesh Chonat, Catherine M. Broome

Blood (2024) 144 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2024-211593

Published: 2024

Journal Articles

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Nichola Cooper, David J Kuter, Henrik Frederiksen, Bing Han, Frederick Chen, Wilma Barcellini, Joan Cid, Catherine M. Broome, Míriam Vara, Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M Risitano, Sumit Sawhney, Quentin A. Hill, Deepthi Jayawardene, Remco Diab, Jing Zhao, Ahmed Daak

Blood (2024) 144 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2024-200325

Published: 2024

Journal Articles

A Novel Online Decision Support Tool to Determine Practice Patterns and Concordance with Experts in the Treatment of Patients with Immune Thrombocytopenia

Jacqueline L. Olin, Catherine M. Broome, Sandhya R Panch, Kristen Rosenthal, Timothy A. Quill, Kristin A. Shimano, Hanny Al-Samkari

Blood (2023) 142 (Supplement 1): 5046.

https://doi.org/10.1182/blood-2023-182029

Published: 2023

Journal Articles

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2023) 142 (Supplement 1): 689.

https://doi.org/10.1182/blood-2023-189125

Published: 2023

Journal Articles

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Alexander Roeth, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Marc Michel, Quentin A. Hill, Shruti Srivastava, Ronnie Yoo, Catherine M. Broome

Blood (2023) 142 (Supplement 1): 7341.

https://doi.org/10.1182/blood-2023-180678

Published: 2023

Journal Articles

Combined Safety Data for Sutimlimab in Cold Agglutinin Disease: A Post-Hoc Analysis of the Phase 3 Cardinal and Cadenza Studies

Catherine M. Broome, Wilma Barcellini, Yasutaka Ueda, Umer Khan, Reena Patel, Marek Wardęcki, Katarina Kralova, Shruti Srivastava, Alexander Roeth

Blood (2023) 142 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2023-188686

Published: 2023

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Journal Articles

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Irina Murakhovskaya, Michelle Lee, Frank Shafer, Marek Wardecki, Jennifer Wang, Ronnie Yoo, Jerome Mshijid, Ilene C. Weitz

Blood (2022) 140 (Supplement 1): 70–72.

https://doi.org/10.1182/blood-2022-159966

Published: 2022

Journal Articles

Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US

Catherine M. Broome, Jon P. Fryzek, Lauren C. Bylsma, Meghan E. Mitchell, Nawar M. Shara, Stephen J. Fernandez, Joseph P. Catlett, Todd L. Edwards, Daniel J. Hausrath, Loren P. Lipworth, Jacob S. Lai, Kathy Dong, Naval Daver, Carl E. Allen

Blood (2022) 140 (Supplement 1): 5490–5491.

https://doi.org/10.1182/blood-2022-167819

Published: 2022

Journal Articles

Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies

Bruno Fattizzo, Alexander Roeth, Catherine M. Broome, Umer Khan, Frank Shafer, Matias Cordoba, Wilma Barcellini

Blood (2022) 140 (Supplement 1): 2839–2841.

https://doi.org/10.1182/blood-2022-159988

Published: 2022

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Catherine M. Broome, Wilma Barcellini, Alexander Roeth, Alia Karaouni, Florence Joly, Ronnie Yoo, Augustin Terlinden, Ayo Adeyemi, Yola Moride, Quentin A. Hill

Blood (2022) 140 (Supplement 1): 5306–5308.

https://doi.org/10.1182/blood-2022-163232

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood (2022) 140 (9): 980–991.

https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Waleed Ghanima, Vickie McDonald, Shivi Jain, Monica Carpenedo, Esther N. Oliva, Anna Hultberg, Domenica Gandini, Erik Hofman, Tonke Van Bragt, Wim Parys, Benjamin van Hoorick, Yoshitaka Miyakawa, Catherine M. Broome

Blood (2021) 138 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2021-153261

Published: 2021

Journal Articles

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood (2021) 138 (Supplement 1): 349.

https://doi.org/10.1182/blood-2021-148066

Published: 2021

Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136219

Published: 2020

NARROW

Anti-Complement Therapy Decreases Endogenous Thrombin Potential in Patients with Cold Agglutinin Disease

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

A Novel Online Decision Support Tool to Determine Practice Patterns and Concordance with Experts in the Treatment of Patients with Immune Thrombocytopenia

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Combined Safety Data for Sutimlimab in Cold Agglutinin Disease: A Post-Hoc Analysis of the Phase 3 Cardinal and Cadenza Studies

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US

Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only